{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:04Z","timestamp":1783332964731,"version":"3.54.6"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00784-y","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:27:56Z","timestamp":1778869676000},"page":"607-621","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen\u2013Directed CAR T-Cell Therapy"],"prefix":"10.1007","volume":"40","author":[{"given":"Maria T.","family":"Kuipers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorne","family":"Migchelbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marijn","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde C. M.","family":"Kouwenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaz","family":"Groen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1251-4649","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"issue":"6","key":"784_CR1","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk NWCJ, Usmani SZ, Yong K. CAR T-cell therapy for multiple myeloma: state of the art and prospects. Lancet Haematol. 2021;8(6):e446\u201361. https:\/\/doi.org\/10.1016\/S2352-3026(21)00057-0.","journal-title":"Lancet Haematol"},{"issue":"15_suppl","key":"784_CR2","doi-asserted-by":"publisher","first-page":"8041","DOI":"10.1200\/JCO.2021.39.15_suppl.8041","volume":"39","author":"M-V Mateos","year":"2021","unstructured":"Mateos M-V, Weisel K, Stefano VD, et al. LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed\/refractory multiple myeloma (RRMM) receiving \u2265 3 prior lines of therapy. J Clin Oncol. 2021;39(15_suppl):8041\u20138041. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.8041.","journal-title":"J Clin Oncol"},{"issue":"8","key":"784_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"issue":"10297","key":"784_CR4","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/s0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021;398(10297):314\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(21)00933-8.","journal-title":"Lancet"},{"issue":"23","key":"784_CR5","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Arnulf B, Patel K, et al. Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood. 2024;144(23):2389\u2013401. https:\/\/doi.org\/10.1182\/blood.2024024582.","journal-title":"Blood"},{"key":"784_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00653-9","author":"H Einsele","year":"2026","unstructured":"Einsele H, San-Miguel J, Dhakal B, et al. Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2026. https:\/\/doi.org\/10.1016\/S1470-2045(25)00653-9.","journal-title":"Lancet Oncol"},{"issue":"4","key":"784_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2303379.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"784_CR8","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2025-804","volume":"146","author":"JH Noll","year":"2025","unstructured":"Noll JH, Ho M, Paruzzo L, et al. Delayed neurotoxicity, enterocolitis, and BCMA-CART-associated immune-related adverse events (CirAE) are caused by CD4+ CAR T-cells. Blood. 2025;146(Supplement 1):804\u2013804. https:\/\/doi.org\/10.1182\/blood-2025-804.","journal-title":"Blood"},{"issue":"Supplement 1","key":"784_CR9","doi-asserted-by":"publisher","first-page":"5945","DOI":"10.1182\/blood-2025-5945","volume":"146","author":"L Paruzzo","year":"2025","unstructured":"Paruzzo L, Ho M, Noll JH, et al. CCR5 blockade: a therapeutic approach to uncouple CART-BCMA expansion from CART-mediated immune toxicities. Blood. 2025;146(Supplement 1):5945\u20135945. https:\/\/doi.org\/10.1182\/blood-2025-5945.","journal-title":"Blood"},{"issue":"Supplement 1","key":"784_CR10","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2025-2215","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Iida S, Sidiqi MH, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Blood. 2025;146(Supplement 1):2215\u20132215. https:\/\/doi.org\/10.1182\/blood-2025-2215.","journal-title":"Blood"},{"issue":"4","key":"784_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"784_CR12","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2213614.","journal-title":"N Engl J Med"},{"issue":"2","key":"784_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2024026216","volume":"146","author":"S Sidana","year":"2025","unstructured":"Sidana S, Ahmed N, Akhtar OS, et al. Standard-of-care idecabtagene vicleucel for relapsed\/refractory multiple myeloma. Blood. 2025;146(2):167\u201377. https:\/\/doi.org\/10.1182\/blood.2024026216.","journal-title":"Blood"},{"issue":"1","key":"784_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"issue":"8","key":"784_CR15","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/s1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374\u201387. https:\/\/doi.org\/10.1016\/s1470-2045(24)00094-9.","journal-title":"Lancet Oncol"},{"issue":"7","key":"784_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29(7):430\u20137. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.001.","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"784_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1182\/blood.2023020571","volume":"142","author":"P Karschnia","year":"2023","unstructured":"Karschnia P, Miller KC, Yee AJ, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142(14):1243\u20138. https:\/\/doi.org\/10.1182\/blood.2023020571.","journal-title":"Blood"},{"issue":"2","key":"784_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12(2):32. https:\/\/doi.org\/10.1038\/s41408-022-00629-1.","journal-title":"Blood Cancer J"},{"key":"784_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01441-3","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Tan M, Parrondo R, et al. Clinical course, risk factors and mitigating strategies for immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma. Blood Cancer J. 2025. https:\/\/doi.org\/10.1038\/s41408-025-01441-3.","journal-title":"Blood Cancer J"},{"issue":"23","key":"784_CR20","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/blood.2024028172","volume":"145","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Puliafito BR, Graham CE, et al. Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood. 2025;145(23):2788\u201393. https:\/\/doi.org\/10.1182\/blood.2024028172.","journal-title":"Blood"},{"issue":"Supplement 1","key":"784_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1182\/blood-2025-1034","volume":"146","author":"S Sidana","year":"2025","unstructured":"Sidana S, Reid B, Dima D, et al. Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality. Blood. 2025;146(Supplement 1):1034\u20131034. https:\/\/doi.org\/10.1182\/blood-2025-1034.","journal-title":"Blood"},{"issue":"12","key":"784_CR22","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27(12):2099\u2013103. https:\/\/doi.org\/10.1038\/s41591-021-01564-7.","journal-title":"Nat Med"},{"issue":"7","key":"784_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.131","volume":"8","author":"A Couturier","year":"2024","unstructured":"Couturier A, Escoffre M, Leh F, et al. Parkinson-like neurotoxicity in female patients treated with idecabtagene-vicleucel. Hemasphere. 2024;8(7):e131. https:\/\/doi.org\/10.1002\/hem3.131.","journal-title":"Hemasphere"},{"key":"784_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.2506","author":"JA Gudera","year":"2024","unstructured":"Gudera JA, Baehring JM, Karschnia P. Parkinsonism following chimeric antigen receptor T cell therapy. JAMA Neurol. 2024. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2506.","journal-title":"JAMA Neurol"},{"issue":"2","key":"784_CR25","doi-asserted-by":"publisher","first-page":"71.e1","DOI":"10.1016\/j.jtct.2024.12.002","volume":"31","author":"M Ellithi","year":"2025","unstructured":"Ellithi M, Elsallab M, Lunning MA, et al. Neurotoxicity and rare adverse events in BCMA-directed CAR T cell therapy: a comprehensive analysis of real-world FAERS data. Transplant Cell Ther. 2025;31(2):71.e1-71.e14. https:\/\/doi.org\/10.1016\/j.jtct.2024.12.002.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"784_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01410-w","volume":"15","author":"P Rodr\u00edguez-Otero","year":"2025","unstructured":"Rodr\u00edguez-Otero P, Sidana S, Kouwenhoven M, et al. Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed\/refractory MM in CARTITUDE-1, -2, and -4. Blood Cancer J. 2025;15(1):209. https:\/\/doi.org\/10.1038\/s41408-025-01410-w.","journal-title":"Blood Cancer J"},{"issue":"Supplement 1","key":"784_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1182\/blood-2025-96","volume":"146","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Velayati A, Dima D, et al. Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146(Supplement 1):96\u201396. https:\/\/doi.org\/10.1182\/blood-2025-96.","journal-title":"Blood"},{"issue":"2, Supplement","key":"784_CR28","doi-asserted-by":"publisher","first-page":"S215","DOI":"10.1016\/j.jtct.2025.01.330","volume":"31","author":"J Turner","year":"2025","unstructured":"Turner J, Forsberg PA, Nicholson S, Schade H, Matous J, Gregory TK. Prophylactic dexamethasone rescues unrestrained lymphocyte expansion in anti-BCMA chimeric antigen receptor T cell therapy in multiple myeloma. Transplant Cell Ther. 2025;31(2, Supplement):S215\u20136. https:\/\/doi.org\/10.1016\/j.jtct.2025.01.330.","journal-title":"Transplant Cell Ther"},{"issue":"2, Supplement","key":"784_CR29","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.jtct.2025.12.027","volume":"32","author":"KJC Lim","year":"2026","unstructured":"Lim KJC, Parrondo RD, Chhabra S, et al. Investigating the role of dexamethasone prophylaxis for the risk reduction of immune effector cell delayed neurotoxicity in Cilta-Cel treated patients. Transplant Cell Ther. 2026;32(2, Supplement):S12. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.027.","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"784_CR30","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1182\/blood.2023021429","volume":"142","author":"CE Graham","year":"2023","unstructured":"Graham CE, Lee WH, Wiggin HR, et al. Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity. Blood. 2023;142(14):1248\u201352. https:\/\/doi.org\/10.1182\/blood.2023021429.","journal-title":"Blood"},{"issue":"14","key":"784_CR31","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.1182\/bloodadvances.2024015721","volume":"9","author":"K Kelly","year":"2025","unstructured":"Kelly K, Cooperrider JH, Bishop MR, Kosuri S, Jakubowiak A, Derman BA. Intrathecal chemotherapy for ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity. Blood Adv. 2025;9(14):3613\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2024015721.","journal-title":"Blood Adv"},{"issue":"10","key":"784_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood. 2023;142(10):865\u201377. https:\/\/doi.org\/10.1182\/blood.2023020578.","journal-title":"Blood"},{"issue":"6","key":"784_CR33","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/s2352-3026(24)00077-2","volume":"11","author":"K Rejeski","year":"2024","unstructured":"Rejeski K, Jain MD, Shah NN, Perales MA, Subklewe M. Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management. Lancet Haematol. 2024;11(6):e459\u201370. https:\/\/doi.org\/10.1016\/s2352-3026(24)00077-2.","journal-title":"Lancet Haematol"},{"issue":"2","key":"784_CR34","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.jcyt.2022.11.001","volume":"25","author":"L Wang","year":"2023","unstructured":"Wang L, Hong R, Zhou L, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy. Cytotherapy. 2023;25(2):192\u2013201. https:\/\/doi.org\/10.1016\/j.jcyt.2022.11.001.","journal-title":"Cytotherapy"},{"issue":"20","key":"784_CR35","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1158\/1078-0432.Ccr-25-1587","volume":"31","author":"ZM Avigan","year":"2025","unstructured":"Avigan ZM, Catlett J, Bodnar S, et al. Clonal hematopoiesis and inflammation predict hematologic toxicity and secondary myeloid malignancies after B-Cell maturation antigen-directed chimeric antigen receptor T-cell therapy. Clin Cancer Res. 2025;31(20):4333\u201344. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-1587.","journal-title":"Clin Cancer Res"},{"issue":"Supplement 1","key":"784_CR36","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1182\/blood-2025-1035","volume":"146","author":"C Varga","year":"2025","unstructured":"Varga C, Robinson M, Davis J, et al. Outcomes of stem cell boost (SCB) versus supportive care alone for prolonged cytopenias after chimeric antigen receptor T cell therapy (CAR-T) in relapsed\/refractory multiple myeloma (RRMM): a muli-center real-world analysis. Blood. 2025;146(Supplement 1):1035\u20131035. https:\/\/doi.org\/10.1182\/blood-2025-1035.","journal-title":"Blood"},{"issue":"7","key":"784_CR37","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","volume":"29","author":"MR Hines","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29(7):438.e1-438.e16. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","journal-title":"Transplant Cell Ther"},{"key":"784_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.947","author":"S Irfan","year":"2025","unstructured":"Irfan S, Ayoobkhan FS, Vojjala N, et al. Immune effector cell-associated HLH-like syndrome (IEC-HS) in CAR-T and TCE-treated myeloma and B-cell malignancies: insights from a pharmacovigilance study. Transplant Cell Ther. 2025. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.947.","journal-title":"Transplant Cell Ther."},{"issue":"11","key":"784_CR39","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jcyt.2023.06.008","volume":"25","author":"C Zu","year":"2023","unstructured":"Zu C, Wu S, Zhang M, et al. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Cytotherapy. 2023;25(11):1167\u201375. https:\/\/doi.org\/10.1016\/j.jcyt.2023.06.008.","journal-title":"Cytotherapy"},{"key":"784_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1654096","volume":"16","author":"D Mun\u00e1rriz","year":"2025","unstructured":"Mun\u00e1rriz D, Rodr\u00edguez-Lobato LG, L\u00f3pez-Corral L, et al. Macrophage activation syndrome-like in multiple myeloma patients treated with the academic CAR-T against BCMA ARI0002h. Front Immunol. 2025;16:1654096. https:\/\/doi.org\/10.3389\/fimmu.2025.1654096.","journal-title":"Front Immunol"},{"issue":"3","key":"784_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1080\/1744666x.2024.2444673","volume":"21","author":"JM Wang","year":"2025","unstructured":"Wang JM, Jiang HW, Zhang YQ, Hu Y, Mei H. Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies. Expert Rev Clin Immunol. 2025;21(3):277\u201389. https:\/\/doi.org\/10.1080\/1744666x.2024.2444673.","journal-title":"Expert Rev Clin Immunol"},{"issue":"Supplement 1","key":"784_CR42","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1182\/blood-2024-198688","volume":"144","author":"AM Kramer","year":"2024","unstructured":"Kramer AM, Murty T, Chen Y, et al. CD22-directed CAR T Cell single cell multiomic features associated with immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). Blood. 2024;144(Supplement 1):911\u2013911. https:\/\/doi.org\/10.1182\/blood-2024-198688.","journal-title":"Blood"},{"key":"784_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215149","author":"T Fugere","year":"2023","unstructured":"Fugere T, Baltz A, Mukherjee A, et al. Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15215149.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"784_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41408-024-01167-8","volume":"14","author":"GG Fortuna","year":"2024","unstructured":"Fortuna GG, Banerjee R, Savid-Frontera C, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14(1):180. https:\/\/doi.org\/10.1038\/s41408-024-01167-8.","journal-title":"Blood Cancer J"},{"key":"784_CR45","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/S2152-2650(24)01911-6","volume":"24","author":"N Bar","year":"2024","unstructured":"Bar N, Yee A, Dhakal B, et al. P-008 a rare and unexplored entity of colitis post-BCMA directed CAR T-cell therapy; Insights from a multicenter case series. Clin Lymphoma Myeloma Leuk. 2024;24:S44\u20135. https:\/\/doi.org\/10.1016\/S2152-2650(24)01911-6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10S","key":"784_CR46","doi-asserted-by":"publisher","first-page":"S1906","DOI":"10.14309\/01.ajg.0001040340.34259.b1","volume":"119","author":"R Bashir Hamidu","year":"2024","unstructured":"Bashir Hamidu R, Von Rosenvinge E. S2743\u2003CAR T-cell therapy-induced pseudomembranous colitis mimicking C. difficile infection. Am J Gastroenterol. 2024;119(10S):S1906. https:\/\/doi.org\/10.14309\/01.ajg.0001040340.34259.b1.","journal-title":"Am J Gastroenterol"},{"key":"784_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2025.105791","volume":"158","author":"SS Karimi","year":"2025","unstructured":"Karimi SS, Larman TC, Jain T, Voltaggio L, Birkness-Gartman JE. Chimeric antigen receptor (CAR) T-cell therapy-related gastrointestinal toxicity: histologic features and morphologic mimics. Hum Pathol. 2025;158:105791. https:\/\/doi.org\/10.1016\/j.humpath.2025.105791.","journal-title":"Hum Pathol"},{"key":"784_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000002499","author":"L Osnis","year":"2025","unstructured":"Osnis L, Hart J, Olivas A, et al. Patterns of gastrointestinal injury associated with CAR-T therapy for patients with multiple myeloma. Am J Surg Pathol. 2025. https:\/\/doi.org\/10.1097\/pas.0000000000002499.","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"784_CR49","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.it.2017.10.006","volume":"39","author":"FL Jahnsen","year":"2018","unstructured":"Jahnsen FL, B\u00e6kkevold ES, Hov JR, Landsverk OJ. Do long-lived plasma cells maintain a healthy microbiota in the gut? Trends Immunol. 2018;39(3):196\u2013208. https:\/\/doi.org\/10.1016\/j.it.2017.10.006.","journal-title":"Trends Immunol"},{"issue":"Supplement 1","key":"784_CR50","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1182\/blood-2025-690","volume":"146","author":"D Fandrei","year":"2025","unstructured":"Fandrei D, Seiffert S, Kuhn C, et al. Spatiotemporal and genetic tracking of long-term persisting CAR-T cells following ciltacabtagene autoleucel treatment for multiple myeloma reveals molecular insights into late-onset toxicities. Blood. 2025;146(Supplement 1):690\u2013690. https:\/\/doi.org\/10.1182\/blood-2025-690.","journal-title":"Blood"},{"issue":"2","key":"784_CR51","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1016\/j.jtct.2025.12.229","volume":"32","author":"MP Hamilton","year":"2026","unstructured":"Hamilton MP, Dong S, Sainz TP, et al. Ciltacabtagene Autoleucel immune effector cell enteritis\/colitis is driven by persistent clonal CAR+ T-Cells. Transplant Cell Ther. 2026;32(2):S167\u20138. https:\/\/doi.org\/10.1016\/j.jtct.2025.12.229.","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"784_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01319-4","volume":"15","author":"K Somay","year":"2025","unstructured":"Somay K, Azakli H, Chahine JJ, Loughney TM, Ozdemirli M. Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder? Blood Cancer J. 2025;15(1):117. https:\/\/doi.org\/10.1038\/s41408-025-01319-4.","journal-title":"Blood Cancer J"},{"key":"784_CR53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19510","author":"M Jaberi-Douraki","year":"2025","unstructured":"Jaberi-Douraki M, Ampadi Ramachandran R, Xu X, et al. Comparative assessment of colitis-related adverse events in multiple myeloma patients treated with teclistamab, ciltacabtagene, and idecabtagene: Incidence, outcomes, and risk assessment. J Clin Oncol. 2025. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e19510.","journal-title":"J Clin Oncol"},{"issue":"1","key":"784_CR54","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41408-025-01320-x","volume":"15","author":"R Banerjee","year":"2025","unstructured":"Banerjee R, Hosoya H, Mikkilineni L, Hansen DK, Wolf JL, Lin Y. Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma. Blood Cancer J. 2025;15(1):112. https:\/\/doi.org\/10.1038\/s41408-025-01320-x.","journal-title":"Blood Cancer J"},{"issue":"6","key":"784_CR55","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, et al. CD4+ T-Cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392(6):577\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2411507.","journal-title":"N Engl J Med"},{"key":"784_CR56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031423","author":"H Hosoya","year":"2025","unstructured":"Hosoya H, Bastidas Torres AN, Fernandez-Pol S, et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025031423.","journal-title":"Blood"},{"issue":"4","key":"784_CR57","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s41591-025-03499-9","volume":"31","author":"T Braun","year":"2025","unstructured":"Braun T, Rade M, Merz M, et al. Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody. Nat Med. 2025;31(4):1145\u201353. https:\/\/doi.org\/10.1038\/s41591-025-03499-9.","journal-title":"Nat Med"},{"issue":"22","key":"784_CR58","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli M, Loughney TM, Deniz E, et al. Indolent CD4+ CAR T-Cell lymphoma after Cilta-cel CAR T-Cell therapy. N Engl J Med. 2024;390(22):2074\u201382. https:\/\/doi.org\/10.1056\/NEJMoa2401530.","journal-title":"N Engl J Med"},{"key":"784_CR59","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1182\/blood-2024-207885","volume":"144","author":"H Hosoya","year":"2024","unstructured":"Hosoya H, Fernandez-Pol S, Gubatan J, et al. Indolent CD8+ CAR T-cell lymphoma of the gastrointestinal tract after Ciltacabtagene Autoleucel therapy for relapsed\/refractory multiple myeloma. Blood. 2024;144:4846. https:\/\/doi.org\/10.1182\/blood-2024-207885.","journal-title":"Blood"},{"key":"784_CR60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abb4432","author":"BS Boland","year":"2020","unstructured":"Boland BS, He Z, Tsai MS, et al. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020. https:\/\/doi.org\/10.1126\/sciimmunol.abb4432.","journal-title":"Sci Immunol"},{"issue":"Supplement 1","key":"784_CR61","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2025-2392","volume":"146","author":"V Blumenberg","year":"2025","unstructured":"Blumenberg V, Birocchi F, Shih A, et al. Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T-cell therapy for multiple myeloma. Blood. 2025;146(Supplement 1):2392\u20132392. https:\/\/doi.org\/10.1182\/blood-2025-2392.","journal-title":"Blood"},{"key":"784_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101161","volume":"47","author":"ME Agha","year":"2026","unstructured":"Agha ME, McGregor S, De Braganca KC, et al. Systematic literature review of secondary primary malignancies related to a CAR-T treatment in patients with multiple myeloma, lymphoma or leukemia. Cancer Treat Res Commun. 2026;47:101161. https:\/\/doi.org\/10.1016\/j.ctarc.2026.101161.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"784_CR63","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, Hexner EO, Marshall A, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025;31(4):1134\u201344. https:\/\/doi.org\/10.1038\/s41591-024-03478-6.","journal-title":"Nat Med"},{"issue":"20","key":"784_CR64","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, et al. Second primary malignancies after CAR T-cell therapy: a systematic review and meta-analysis of 5,517 lymphoma and myeloma patients. Clin Cancer Res. 2024;30(20):4690\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1798.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"784_CR65","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/nrmicro1263","volume":"3","author":"F Bushman","year":"2005","unstructured":"Bushman F, Lewinski M, Ciuffi A, et al. Genome-wide analysis of retroviral DNA integration. Nat Rev Microbiol. 2005;3(11):848\u201358. https:\/\/doi.org\/10.1038\/nrmicro1263.","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"784_CR66","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584\u20136. https:\/\/doi.org\/10.1056\/NEJMp2400209.","journal-title":"N Engl J Med"},{"issue":"22","key":"784_CR67","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390(22):2047\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2401361.","journal-title":"N Engl J Med"},{"issue":"4","key":"784_CR68","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02826-w.","journal-title":"Nat Med"},{"issue":"4","key":"784_CR69","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1038\/s41591-024-03458-w","volume":"31","author":"R Dulery","year":"2025","unstructured":"Dulery R, Guiraud V, Choquet S, et al. T cell malignancies after CAR T cell therapy in the DESCAR-T registry. Nat Med. 2025;31(4):1130\u20133. https:\/\/doi.org\/10.1038\/s41591-024-03458-w.","journal-title":"Nat Med"},{"issue":"10","key":"784_CR70","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jtct.2024.06.027","volume":"30","author":"R Lorenc","year":"2024","unstructured":"Lorenc R, Shouval R, Flynn JR, et al. Subsequent malignancies after CD19-targeted chimeric antigen receptor T cells in patients with lymphoma. Transplant Cell Ther. 2024;30(10):990\u20131000. https:\/\/doi.org\/10.1016\/j.jtct.2024.06.027.","journal-title":"Transplant Cell Ther."},{"key":"784_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-025-00586-x","author":"P Berg","year":"2025","unstructured":"Berg P, Bakker C, Sander M, et al. Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA\u2019s conclusions from the evaluation of 38 suspected cases. Gene Ther. 2025. https:\/\/doi.org\/10.1038\/s41434-025-00586-x.","journal-title":"Gene Ther"},{"issue":"Supplement 1","key":"784_CR72","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1182\/blood-2025-5852","volume":"146","author":"E Zolotov","year":"2025","unstructured":"Zolotov E, Biran N, Roney P, et al. Subsequent primary malignancies after CAR-T therapy: a study from the US multiple myeloma immunotherapy consortium. Blood. 2025;146(Supplement 1):5852\u20135852. https:\/\/doi.org\/10.1182\/blood-2025-5852.","journal-title":"Blood"},{"issue":"9","key":"784_CR73","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1038\/s41591-023-02496-0","volume":"29","author":"Y Lin","year":"2023","unstructured":"Lin Y, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286\u201394. https:\/\/doi.org\/10.1038\/s41591-023-02496-0.","journal-title":"Nat Med"},{"issue":"6","key":"784_CR74","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265\u201374. https:\/\/doi.org\/10.1200\/jco.22.00842.","journal-title":"J Clin Oncol"},{"issue":"12","key":"784_CR75","doi-asserted-by":"publisher","first-page":"e906","DOI":"10.1016\/s2352-3026(22)00289-7","volume":"9","author":"K Saleem","year":"2022","unstructured":"Saleem K, Franz J, Klem ML, et al. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis. Lancet Haematol. 2022;9(12):e906\u201318. https:\/\/doi.org\/10.1016\/s2352-3026(22)00289-7.","journal-title":"Lancet Haematol"},{"issue":"10","key":"784_CR76","doi-asserted-by":"publisher","first-page":"e838","DOI":"10.1016\/s2352-3026(23)00212-0","volume":"10","author":"T Trab","year":"2023","unstructured":"Trab T, Baech J, Jakobsen LH, et al. Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study. Lancet Haematol. 2023;10(10):e838\u201348. https:\/\/doi.org\/10.1016\/s2352-3026(23)00212-0.","journal-title":"Lancet Haematol"},{"key":"784_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14092278","author":"M Chahin","year":"2022","unstructured":"Chahin M, Branham Z, Fox A, Leurinda C, Keruakous AR. Clinical considerations for immunoparesis in multiple myeloma. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14092278.","journal-title":"Cancers (Basel)"},{"key":"784_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(24)01993-1","volume":"24","author":"N van de Donk","year":"2024","unstructured":"van de Donk N, Mart\u00ednez-Lopez J, Dhakal B, et al. P-090 infections and immune reconstitution in the phase 3 CARTITUDE-4 trial of Ciltacabtagene Autoleucel vs standard care in patients with Lenalidomide-Refractory multiple myeloma (MM) and 1\u20133 prior lines. Clin Lymphoma Myeloma Leuk. 2024;24:S94. https:\/\/doi.org\/10.1016\/S2152-2650(24)01993-1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"784_CR79","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667\u201378. https:\/\/doi.org\/10.1038\/s41591-024-03084-6.","journal-title":"Nat Med"},{"issue":"4","key":"784_CR80","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/bjh.19302","volume":"204","author":"D Dima","year":"2024","unstructured":"Dima D, Rashid A, Davis JA, et al. Efficacy and safety of idecabtagene vicleucel in patients with relapsed-refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: a real-world multicentre study. Br J Haematol. 2024;204(4):1293\u20139. https:\/\/doi.org\/10.1111\/bjh.19302.","journal-title":"Br J Haematol"},{"issue":"6","key":"784_CR81","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1182\/bloodadvances.2024015008","volume":"9","author":"T Richardson","year":"2025","unstructured":"Richardson T, Sch\u00fctte D, Kobbe G, et al. Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis. Blood Adv. 2025;9(6):1370\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2024015008.","journal-title":"Blood Adv"},{"key":"784_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02752-1","volume":"25","author":"A Yadav","year":"2025","unstructured":"Yadav A, Khetarpal M, Jain A. CT-062: navigating the toxicity landscape of BCMA-directed CAR-T therapies in multiple myeloma: a systematic review of CAR-T therapies. Clin Lymphoma Myeloma Leuk. 2025;25:S1001. https:\/\/doi.org\/10.1016\/S2152-2650(25)02752-1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"784_CR83","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2024013461","volume":"8","author":"H Ludwig","year":"2024","unstructured":"Ludwig H, Munshi NC, Terpos E, et al. Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma. Blood Adv. 2024;8(18):4979\u201382. https:\/\/doi.org\/10.1182\/bloodadvances.2024013461.","journal-title":"Blood Adv"},{"issue":"4","key":"784_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70040","volume":"27","author":"T Kikuchi","year":"2025","unstructured":"Kikuchi T, Watanabe M, Tsukada N, et al. Cytomegalovirus retinitis during Idecabtagene Vicleucel therapy in patients with relapsed\/refractory multiple myeloma. Transpl Infect Dis. 2025;27(4):e70040. https:\/\/doi.org\/10.1111\/tid.70040.","journal-title":"Transpl Infect Dis"},{"issue":"10","key":"784_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00563-8","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Mao X, Que Y, et al. Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy. Blood Cancer J. 2021;11(10):168. https:\/\/doi.org\/10.1038\/s41408-021-00563-8.","journal-title":"Blood Cancer J"},{"issue":"3","key":"784_CR86","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/ejh.13909","volume":"110","author":"BW Hoeynck","year":"2023","unstructured":"Hoeynck BW, Cohen AD, Stadtmauer EA, et al. Progressive multifocal leukoencephalopathy in multiple myeloma. Eur J Haematol. 2023;110(3):322\u20139. https:\/\/doi.org\/10.1111\/ejh.13909.","journal-title":"Eur J Haematol"},{"key":"784_CR87","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2025.16.7.16","author":"M Abreu","year":"2025","unstructured":"Abreu M, Patel CB, Patel K, Khawaja F, Tummala S. Progressive multifocal leukoencephalopathy in chimeric antigen receptor T-Cell therapy recipients: a case study. J Adv Pract Oncol. 2025. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.16.","journal-title":"J Adv Pract Oncol"},{"issue":"Suppl 1(Suppl 1","key":"784_CR88","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14109","volume":"25","author":"G Reynolds","year":"2023","unstructured":"Reynolds G, Hall VG, Teh BW. Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy. Transpl Infect Dis. 2023;25(Suppl 1(Suppl 1)):e14109. https:\/\/doi.org\/10.1111\/tid.14109.","journal-title":"Transpl Infect Dis"},{"issue":"Supplement 1","key":"784_CR89","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2025-2214","volume":"146","author":"D Hansen","year":"2025","unstructured":"Hansen D, Reid B, Grajales-Cruz A, et al. Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146(Supplement 1):2214\u20132214. https:\/\/doi.org\/10.1182\/blood-2025-2214.","journal-title":"Blood"},{"issue":"1","key":"784_CR90","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2643-3230.Bcd-24-0118","volume":"6","author":"D Fandrei","year":"2025","unstructured":"Fandrei D, Seiffert S, Rade M, et al. Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma. Blood Cancer Discov. 2025;6(1):38\u201354. https:\/\/doi.org\/10.1158\/2643-3230.Bcd-24-0118.","journal-title":"Blood Cancer Discov"},{"issue":"Supplement 1","key":"784_CR91","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2025-256","volume":"146","author":"K Patel","year":"2025","unstructured":"Patel K, Dhakal B, Kaur G, et al. Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and\/or refractory multiple myeloma: updated results from iMMagine\u20131. Blood. 2025;146(Supplement 1):256\u2013256. https:\/\/doi.org\/10.1182\/blood-2025-256.","journal-title":"Blood"},{"issue":"Supplement 1","key":"784_CR92","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1182\/blood-2025-7644","volume":"146","author":"K Hart","year":"2025","unstructured":"Hart K, Hyde M, Pham C, et al. The fast off-rate of anito-cel\u2019s D-Domain binder contributes to its distinctive pharmacology profile in preclinical models of multiple myeloma. Blood. 2025;146(Supplement 1):7644\u20137644. https:\/\/doi.org\/10.1182\/blood-2025-7644.","journal-title":"Blood"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00784-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00784-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:37:35Z","timestamp":1783330655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00784-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":92,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["784"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00784-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"26 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.W.C.J.v.d.D. has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, CellCentric, Novartis, Cellectis and BMS, and serves on advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Galapagos, Kite Pharma, Merck, Pfizer, AbbVie, and Servier, all paid to institution. S.Z. has received research funding from Takeda and Janssen, and serves on advisory boards for Janssen, Takeda, and BMS, all paid to institution. M.T.K., J.M., A.M.K., M.C.M.K., and K.G. have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"No datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed equally to the writing of this review.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}}]}}